Document Detail

Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer.
MedLine Citation:
PMID:  1955513     Owner:  NLM     Status:  MEDLINE    
A RIA for PTH-related protein (PTHrP) is described, using a polyclonal goat antiserum against synthetic PTHrP-(1-40) and recombinant PTHrP-(1-84) as standard. The detection limit is 2 pmol/L, and intra- and interassay coefficients of variation are 4.8% and 13.6%, respectively. This assay does not detect PTH even at concentrations of up to 2000 pmol/L. Cross-reactivity studies using various synthetic PTHrP peptides localize the antibody-binding epitope between residues 20 and 29. Hypercalcemic patients with a range of solid tumors and no evidence of bone metastases on radionuclide scanning (n = 27) all had detectable PTHrP levels (range, 2.8-51.2 pmol/L). Of 17 patients with solid tumors (other than breast) and bone metastases, 11 (64%) also had detectable PTHrP levels (range, 4.9-47.5 pmol/L). Twenty samples from breast cancer patients with hypercalcemia, 19 with evidence of bone metastases, and 1 with a negative bone scan were assayed, and detectable PTHrP levels were found in 13 (65%; range, 3.8-61.6 pmol/L). Patients with squamous cell carcinomata and normal serum calcium levels (n = 11) had no detectable PTHrP or levels close to the detection limit of the assay (range, less than 2 to 3.7 pmol/L). Plasma levels in normal volunteers were below the detection limit of the assay in all but 1 of 38 normal subjects. Patients with chronic renal failure on hemodialysis (n = 18) and patients with primary hyperparathyroidism (n = 14) all had undetectable PTHrP in this assay. This assay allows positive identification of patients with PTHrP-mediated hypercalcemia and, therefore, should be useful in the clinical investigation of the hypercalcemic patient. Furthermore, it has allowed detection of circulating PTHrP in hypercalcemic breast cancer patients with bone metastases, indicating a significant role for PTHrP in this disease.
V Grill; P Ho; J J Body; N Johanson; S C Lee; S C Kukreja; J M Moseley; T J Martin
Related Documents :
3538453 - The role of ultrasonography in the evaluation of primary hyperparathyroidism.
3582723 - Vitamin c status of elderly patients on admission into an assessment geriatric ward.
3559643 - A clinical, eeg and ct study in 21 cases of chronic respiratory failure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  73     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1991 Dec 
Date Detail:
Created Date:  1992-01-02     Completed Date:  1992-01-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1309-15     Citation Subset:  AIM; IM    
Department of Medicine, St. Vincent's Institute of Medical Research, St. Vincent's Hospital, Fitzroy, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Breast Neoplasms / complications*,  secondary
Hypercalcemia / blood*,  etiology
Hyperparathyroidism / blood
Immune Sera / immunology
Middle Aged
Neoplasm Proteins / analysis
Neoplasms / complications
Osmolar Concentration
Parathyroid Hormone-Related Protein
Proteins / analysis*
Sensitivity and Specificity
Reg. No./Substance:
0/Immune Sera; 0/Neoplasm Proteins; 0/PTHLH protein, human; 0/Parathyroid Hormone-Related Protein; 0/Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
Next Document:  Marked augmentation of nocturnal melatonin secretion in amenorrheic athletes, but not in cycling ath...